Literature DB >> 1648569

Immunoaffinity purification of the NS1 protein of Murray Valley encephalitis virus: selection of the appropriate ligand and optimal conditions for elution.

R A Hall1, R J Coelen, J S Mackenzie.   

Abstract

A novel approach was used to select the most suitable antiviral monoclonal antibody (mAb) and elution conditions for immunoaffinity purification of the NS1 protein of Murray Valley encephalitis virus (MVE). Crude NS1 protein was subjected to a variety of chemical conditions produced by common elution buffers, and tested with a panel of NS1-specific mAbs by ELISA to determine which buffers denatured antigenic epitopes. Buffers that caused least structural damage to NS1 epitopes were tested by ELISA for dissociation of NS1-mAb complexes adsorbed to the solid phase. For each mAb analysed, the conditions required to break the mAb-NS1 complex on the solid phase were similar to those required to release antigen bound to mAb-sepharose beads. From these results we selected an appropriate antibody for affinity purification of the non-structural viral protein NS1 on CNBr-activated sepharose columns. Elution at pH 11.5 yielded good recoveries of highly pure and antigenically intact NS1 dimer. The results demonstrate that the appropriate ligand and optimal elution conditions can be rapidly determined generally by immunoassay in microtitre plates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648569     DOI: 10.1016/0166-0934(91)90180-8

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  2 in total

1.  A novel complex formed between the flavivirus E and NS1 proteins: analysis of its structure and function.

Authors:  B J Blitvich; J S Mackenzie; R J Coelen; M J Howard; R A Hall
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

2.  NS1 protein secretion during the acute phase of West Nile virus infection.

Authors:  Joanne Macdonald; Jessica Tonry; Roy A Hall; Brent Williams; Gustavo Palacios; Mundrigi S Ashok; Omar Jabado; David Clark; Robert B Tesh; Thomas Briese; W Ian Lipkin
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.